The post How Stellar (XLM) became part of DTCC’s plan to bring securities onchain appeared on BitcoinEthereumNews.com. DTCC’s decision to connect its upcoming tokenizedThe post How Stellar (XLM) became part of DTCC’s plan to bring securities onchain appeared on BitcoinEthereumNews.com. DTCC’s decision to connect its upcoming tokenized

How Stellar (XLM) became part of DTCC’s plan to bring securities onchain

2026/06/01 01:07
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 [email protected]으로 연락주시기 바랍니다

DTCC’s decision to connect its upcoming tokenized securities platform to the Stellar (XLM) network is the latest step in a relationship that stretches back nearly a decade, according to Stellar Development Foundation CEO Denelle Dixon.

Earlier this week, DTCC said tokenized assets held through its Depository Trust Company could become available on Stellar beginning in the first half of 2027.

The move carries weight because DTCC is one of Wall Street’s core market utilities, overseeing more than $114 trillion in assets. The Stellar integration is designed to support the issuance, settlement and lifecycle management of tokenized securities, while opening the door to future projects involving highly liquid assets such as major indexes and U.S. Treasuries

The roots of the partnership go back to Securrency, the institutional tokenization platform DTCC acquired in 2023 and became what is now DTCC Digital Assets.

Securrency, Dixon told CoinDesk in an interview, worked closely with Stellar developers on features regulated financial institutions needed to issue assets onchain, including clawback functionality, compliance controls and transfer restrictions. Those tools were later built directly into the network.

“Some of the team has been working with Stellar for a long time,” Dixon said.

The news landed as tokenization has become one of the dominant themes across both crypto and traditional finance, drawing interest from global banks and asset managers looking to move traditional financial instruments onto blockchain rails.

Tokenization refers to representing assets such as U.S. Treasury bonds, money market funds, stocks or private credit as digital tokens that can be issued, traded and settled on blockchains. Proponents argue the technology could shorten settlement times, free up collateral trapped in legacy processes and eventually allow markets to operate around the clock.

It’s potentially a huge market. Standard Chartered projected $2 trillion in tokenized assets by 2028, while BCG and Ripple forecasted a $18.9 trillion market size by 2033.

Franklin Templeton’s early bet on Stellar

Dixon argued that tokenized assets are only the visible layer of a broader infrastructure shift.

“Blockchain is excellent at books and records,” she said. “Tokenization is the product outcome, but it’s all these underlying components that are really important.”

That focus on record-keeping was one reason Franklin Templeton selected Stellar for its onchain money market fund, BENJI. Dixon said the asset manager began exploring Stellar in 2019 and later launched the fund in 2021, aiming to place fund records on a single shared ledger rather than relying on multiple databases.

BENJI became one of the earliest examples of a regulated tokenized fund and helped pave the way for today’s tokenized Treasury market, which has grown to roughly $15 billion with BlackRock, JPMorgan, Fidelity entering the ring.

Making public blockchains work for regulated finance

For institutions, however, moving assets onchain requires more than faster settlement.

Regulated firms must comply with securities laws, sanctions requirements and investor protections, creating demand for blockchain infrastructure that can support identity checks, transfer restrictions and other compliance controls.

That need for compliance-ready infrastructure is one reason Stellar’s long-standing relationship with Securrency proved valuable, Dixon said.

Stellar’s architecture allows issuers to add compliance, identity controls and privacy protections on top of an open network, she said. Asset issuers can decide whether transfers require know-your-customer (KYC) checks, whether assets can be frozen or clawed back and what transaction information remains visible.

“The base layer is always going to be open,” Dixon said. “Then the institution gets to decide how compliance and privacy come into play.”

Source: https://www.coindesk.com/business/2026/05/31/how-stellar-became-part-of-dtcc-s-tokenization-push-for-wall-street-securities-onchain

시장 기회
Particl 로고
Particl 가격(PART)
$0.1875
$0.1875$0.1875
+6.77%
USD
Particl (PART) 실시간 가격 차트

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, [email protected]으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

추천 콘텐츠

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
공유하기
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
공유하기
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
공유하기
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage